Is RPG LifeScience. overvalued or undervalued?

Nov 03 2025 08:05 AM IST
share
Share Via
As of October 31, 2025, RPG LifeScience is fairly valued with a PE ratio of 35.76, a PEG ratio of 0.84, strong ROCE of 46.94%, and has outperformed the Sensex with a 188.28% return over three years, compared to its peers like Sun Pharma and Cipla.
As of 31 October 2025, RPG LifeScience has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 35.76, a Price to Book Value of 7.51, and an EV to EBITDA of 24.94. In comparison to its peers, Sun Pharma has a PE ratio of 35.35 and an EV to EBITDA of 23.98, while Cipla stands out with a more attractive PE ratio of 22.29 and an EV to EBITDA of 5.55.

RPG LifeScience's PEG ratio of 0.84 indicates potential for growth relative to its price, and the company boasts a strong ROCE of 46.94% and ROE of 21.01%. Notably, the stock has outperformed the Sensex over the past three years, returning 188.28% compared to the Sensex's 38.18%, reinforcing its fair valuation amidst a competitive landscape.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News